New oral drug targets Hard-to-Treat cancers with missing gene
NCT ID NCT07288957
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental oral drug called ABSK131 in people with advanced solid tumors that have lost a gene called MTAP. The study aims to find a safe dose and see if the drug can shrink tumors. About 266 participants will receive the drug daily, and researchers will monitor side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABSK131 (an experimental oral drug)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific genetic change (MTAP deletion).
- What could go wrong
- This is a very early (Phase 1) trial with only 266 participants, so the drug may not prove safe or effective. Side effects are unknown, and it may not work for all tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS (PHASE 1) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 201210, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.